Skip to content
Home/Companies/Biotech/Synthace
Synthace

Synthace

Biotech·United Kingdom·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Synthace?

Synthace is a British Biotech company, currently owned by Sofinnova Partners since 2019.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Crossover Fund I · 2018 · VC

Key facts

HQUnited Kingdom
SectorBiotech
Websitewww.synthace.com

More from Sofinnova Crossover Fund I

Other portfolio companies in the same fund.

GenSight Biologics
GenSight Biologics
Active
BiotechFrance
CellCentric
CellCentric
Active
BiotechUnited Kingdom· 2026
Amolyt Pharma
Amolyt Pharma
Exited 2024
BiotechFrance· 2021
to AstraZeneca
Sphere Bio (formerly Sphere Fluidics)
Sphere Bio (formerly Sphere Fluidics)
Exited 2025
MedTechUK· 2021
to Fluidic Analytics
Artios Pharma
Artios Pharma
Active
BiotechUK· 2020
Calliditas
Calliditas
Exited 2024
BiotechSweden· 2020
to Asahi Kasei

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Synthace?

Synthace is currently owned by Sofinnova Partners, through Sofinnova Crossover Fund I, since 2019.

When did Sofinnova Partners acquire Synthace?

Sofinnova Partners acquired Synthace in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue